

23 September 2014

The Company Announcements Platform

ASX Limited

By E-lodgement

Virax: International Multiple Myeloma Authority Joins Scientific Advisory Board

HIGHLIGHTS

- ***Australian Multiple Myeloma Expert Professor Douglas Joshua appointed to Scientific Advisory Board***
- ***High calibre appointment to further strengthen lead oncology programs***

23 September 2014, Melbourne, Australia: One of Australia's most respected multiple myeloma authorities has been appointed to the Scientific Advisory Board of Australian clinical-stage oncology company Virax Holdings Limited (ASX:VHL).

Professor Douglas Joshua, current Emeritus Professor of Haematology at the Sydney University Medical School and Consultant Haematologist at the Royal Prince Alfred Hospital, will take position with immediate effect.

He will join recently appointed US based breast cancer authority Dr Joseph Sparano on Virax's Scientific Advisory Board.

Announcing the news, Virax Managing Director Dr Robert Crombie said this appointment was pivotal to help drive the company's lead oncology programs in multiple myeloma.

"This is a valuable and strategic appointment for our company as we move to exploit the clinical and commercial opportunity presented by our lead drug candidate GGTI-2418," he said.

"It is essential our clinical programs are underpinned by a world class scientific advisory team with the credentials to support our lead asset into the clinic as expeditiously as possible."

Professor Joshua brings an impeccable scientific background in multiple myeloma, which remains an incurable bone marrow cancer.

In 2011, he became the first Australian to be awarded the Robert A Kyle Lifetime Achievement Award, which is presented by the International Myeloma Foundation and recognises an outstanding physician working in myeloma.

He is also a scientific advisor and member of the International Myeloma Foundation

He serves on the editorial board of numerous journals.

Professor Douglas commented: "Multiple myeloma remains an area of oncology that has a substantial unmet medical need. I look forward to bringing new therapies to market that provide better patient outcomes. "

GGTI-2418 is a novel compound emanating from research at Yale University and the prestigious US based Lee Moffitt Cancer Center.

Early stage Phase 1 clinical trials have demonstrated its safety in cancer patients as a monotherapy.

It is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis (cell death) by downregulating several pivotal oncogenic and tumor survival pathways.

Virax is also pursuing development of GGTI-2418 as a new treatment for breast cancer. Clinical trials are expected to commence in early 2015.

Ends.

For further information contact:

Mr. Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Dr Rob Crombie

Managing Director

Ph: +61 (0) 439 361 331

About Virax

Virax is a clinical-stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. In addition, the company has granted a licence to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products. These are: TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to oropharyngeal(head and neck) cancer, and TG4010 – a treatment for non-small cell lung cancer (NSCLC). The board is actively seeking to expand its asset base with complementary technologies and products to maximise shareholder value.